摘要
原发性玻璃体视网膜淋巴瘤(primary vitreoretinal lymphoma,PVRL)是一种高分化淋巴瘤,属于原发性中枢神经系统淋巴瘤的一种.临床表现无特异性,临床诊断和组织学诊断常较困难,确诊往往需要进行细胞组织病理学、免疫组织化学检查、细胞因子分析及聚合酶链反应检查.细胞免疫病理学检查是诊断的金标准.治疗主要应用大剂量甲氨蝶呤,利妥昔单抗是目前PVRL靶向治疗的研究热点,但由于神经系统受累而预后不佳.随着诊疗方法的改进PVRL患者的无病生存率已提高到4.5年以上.
Primary vitreoretinal lymphoma (PVRL) is a rare and fatal ocular malignancy. PVRL is a subset of primary central nervous system lymphoma (PCNSL) , and lack of characteristic clinical manifes-tations of the disease. PVRL requires invasive procedures for tissue diagnosis. Cytology/pathology, molecular pathology, immunohistochemistry, biophysical technology ( flow cytometry) , and cytokine analysis ( interleukine-10) are often required. The gold standard for diagnosis is cellular immune pathology examination. Approaches to treatment have centered on systemic methotrexate-based chemotherapy. Rituximab is a new meidicine in the treatment of PVRL, especially in the targeted therapy. Despite these advances, prognosis remain poor, and few patients remains disease-free 〉 4.5 years after treatment.
出处
《国际眼科纵览》
2015年第6期422-427,共6页
International Review of Ophthalmology
基金
北京市自然科学基金(7112031)
国家自然科学基金(81272981)
北京市卫生系统高层次卫生技术人才培养计划(2009-3-32)